Navigation Links
High-Dose Chemo Helps Beat Rare Brain Cancer
Date:1/30/2008

Many patients achieved long-term remission without radiation, study finds

WEDNESDAY, Jan. 30 (HealthDay News) -- Most people suffering from a rare brain cancer appear to benefit from high doses of the chemotherapy drug methotrexate, a small study finds.

Primary central nervous system lymphoma (PCNSL) is a type of non-Hodgkin lymphoma that affects the brain. Although it is typically very difficult to treat, it can be cured or sent into long remissions. Current treatment is often a combination of radiation and chemotherapy. Newer approaches involve giving chemotherapy first, and waiting on radiation until the results of chemotherapy are seen.

However, "A subset of these patients with a rare form of non-Hodgkin lymphoma appeared to be cured by chemotherapy alone," explained lead researcher Dr. Tracy Batchelor, from the Massachusetts General Hospital Cancer Center in Boston.

Batchelor, who is executive director of the Stephen E. & Catherine Pappas Center for Neuro-Oncology at the hospital, noted there are about 1,500 new cases of PCNSL diagnosed in the United States each year.

In the study, Batchelor's group treated 25 adults with newly diagnosed PCNSL with a high dose of methotrexate every two weeks for four months, or until there were no signs of the brain tumor. The patients were followed for a minimum of 6.5 years.

The report appears in the Jan. 29 issue of Neurology.

Batchelor's team found that 52 percent of the patients had a complete remission of their cancer and 40 percent had not had a relapse after seven years. Average survival of all patients who received methotrexate was 4.5 years, compared with one year among patients who had radiation therapy.

It's clear that methotrexate is the best drug to treat this tumor, Batchelor said. "The drug attacks cells that are dividing. Other drugs don't have as high a response rate," he explained.

Batchelor noted that it is unusual for a single drug to achieve remission in cancer.

More studies are needed to find the most effective dose of methotrexate and to find a combination therapy that will produce even better results, Batchelor said. "The question is whether adding other drugs will make patients do better," he said.

"We are looking for drugs that act against lymphoma and actually get into the nervous system," Batchelor said. "We have a new trial where we will be adding three additional drugs to methotrexate. We hope we are going to see even more patients achieve long-term remission."

One expert believes that, based on these findings, methotrexate could save many patients from having to undergo harmful brain radiation.

"Methotrexate is to date the most effective reported drug in primary central nervous system lymphoma," said Dr. Paul Graham Fisher, an associate professor of neurology and the Beirne Family Director of Neuro-Oncology at Packard Hospital at Stanford University.

This is encouraging because in some rare instances patients may not need radiation treatment, Fisher said. "As a cautionary note, the numbers of patients are small, and we need to see greater extension of this work, and also with monitoring patients for leukoencephalopathy (destruction of fibers covering nerve cells), apparently seen more widely when used in children with leukemia," he said.

Methotrexate is commonly used in chemotherapy and is also used in treating autoimmune diseases such as Crohn's disease, psoriasis and arthritis.

More information

For more on primary central nervous system lymphoma, visit the U.S. National Cancer Institute.



SOURCES: Tracy Batchelor, M.D., associate professor, neurology, Harvard University, and executive director, Stephen E. & Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center, both in Boston; Paul Graham Fisher, M.D. associate professor, neurology, and the Beirne Family Director of Neuro-Oncology, Packard Hospital, Stanford University, Palo Alto, Calif.; Jan. 29, 2008, Neurology


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. High-Dose Chemo Provides Little Benefit to Breast Cancer Patients
2. High-dose chemo and stem cell transplant shows little or no survival benefit for breast cancer
3. Explaining chemotherapy-associated nausea
4. Combined radiation seed, chemotherapy wafer implants show promise in treating cancerous brain tumors
5. ChemoCentryx Appoints Edward E. Penhoet, Ph.D., to Board of Directors
6. Class of Chemotherapy Drugs Helps Certain Breast Cancer Patients
7. Chemotherapy and tamoxifen reduce risk of second breast cancer
8. Modeling Simulation Predicts Potential Negative Impact on U.S. Blood Supply if ESA Use Limited for Chemotherapy-Induced Anemia
9. Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma
10. Extracellular protein sensitizes ovarian cancer cells to chemotherapy
11. Chemoprevention, naturally: Findings on plant-derived cancer medicines
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
High-Dose Chemo Helps Beat Rare Brain Cancer
(Date:5/26/2017)... ... May 26, 2017 , ... Rob Lowe acts as host and helps educate ... is on hiking in American. Viewers can reconnect with America as it explores some ... , Many consumers have looked for an inventive new place for a family vacation, ...
(Date:5/26/2017)... , ... May 26, 2017 , ... “THE FLINTHILLS FAMILY-Our Journey to the Cross”: the ... Journey to the Cross” is the creation of published authors, Bob and Margaret Massey. ... to say, he is "panther quick and leather tough." His love for others is ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and the ... is the creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist ... Jane. Walter. Walter and Jane have three adult children and a granddaughter. ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success depends ... instruments for research and understanding the basic principles that were designed to drive ... innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories working ...
(Date:5/24/2017)... San Diego, California (PRWEB) , ... May 24, ... ... patient care through innovative medical image management and interpretation, has received U.S. Food ... technology. , Nucleus.io is a web-based, scalable and secure cloud platform for ...
Breaking Medicine News(10 mins):
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals Inc. ... a clinical-stage pharmaceutical company focused on the development ... the Canadian Intellectual Property Office has granted Oramed ... Administration of Exenatide". The patent covers Oramed,s invention ... GLP-1 is an incretin hormone that stimulates ...
Breaking Medicine Technology: